CHARLOTTE, N.C., Oct. 20, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) will present results from Chelsea’s two clinical stage product candidates in its portfolio of metabolically inert antifolate molecules at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting in Philadelphia, Pennsylvania. The presentations will include previously reported results from a Phase II, proof-of concept study of CH-1504 and a Phase I trial of CH-4051.
